Shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR – Get Rating) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.63 and traded as high as $0.95. Acorda Therapeutics shares last traded at $0.90, with a volume of 61,784 shares trading hands.
Analyst Ratings Changes
Separately, StockNews.com raised shares of Acorda Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, January 29th.
Acorda Therapeutics Stock Down 2.3 %
The company’s fifty day simple moving average is $0.86 and its 200-day simple moving average is $0.63. The company has a debt-to-equity ratio of 2.48, a current ratio of 1.71 and a quick ratio of 1.34. The firm has a market capitalization of $21.94 million, a PE ratio of -0.13 and a beta of 1.43.
Hedge Funds Weigh In On Acorda Therapeutics
Acorda Therapeutics Company Profile
Acorda Therapeutics, Inc engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm’s also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22.
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Will Q4 Results Send Zoom Video Stock Higher?
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
- Is Target Stock Aiming For A Breakout In 2023?
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.